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In this study, mechanisms of carbapenem resistance in carbapenem-resistant
but cephalosporin-susceptible (Car-R/Ceph-S) Pseudomonas aeruginosa were
investigated. A total of 243 P. aeruginosa isolates were studied. The disk diffusion
and agar dilution methods were used for determination of antibiotic susceptibility
patterns. AmpC and efflux pump overproductions were detected by phenotypic
methods. The presence of carbapenemase-encoding genes was detected by polymerase
chain reaction (PCR). The expression of OprD, MexAB-OprM, and MexXY-OprM
efflux pumps was assessed by real-time PCR. According to disk diffusion method,
altogether 116 P. aeruginosa isolates (47.7%) were carbapenem-resistant and among
them, 23 isolates (19.8%) were cephalosporin-susceptible. Carbapenemase producer
was not detected. Overexpression of AmpC was detected in one (4.3%) isolate that
was ceftazidime-susceptible but cefepime-resistant. Overexpression of MexAB-OprM
and MexXY-OprM efflux pumps was detected in 12 (60.9%) and 16 (68.8%) of
isolates, respectively. A total of 16 (68.8%) isolates showed decreased expression of
OprD. The Car-R/Ceph-S P. aeruginosa did not develop by carbapenemase
production. The resistance to carbapenem was mediated in our clinical isolates by
decreased expression of OprD and overexpression of MexAB-OprM and MexXY-
OprM efflux systems or the combination of these mechanisms.
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aeruginosa
*Corresponding author; E-mail: y.memar@yahoo.com
Acta Microbiologica et Immunologica Hungarica 66 (4), pp. 529–540 (2019)
DOI: 10.1556/030.66.2019.036
First published online November 11, 2019
1217-8950/$20.00 © 2019 Akadémiai Kiadó, Budapest
Introduction
Pseudomonas aeruginosa is a common bacterial pathogen in healthcare-
associated infections, particularly in immunocompromised patients, and shows
notorious adaptability and capability to acquire resistance mechanisms against
antibiotics [1]. The origin of this opportunistic organism can be endogenous or
exogenous [2]. Infections due to P. aeruginosa are often problematical because of
the high level of intrinsic or acquired resistance to different antimicrobial agents
[1, 3, 4]. The increasing incidence of hospital infections caused by multidrug-
resistant (MDR) P. aeruginosa strains with resistance to broad-spectrum β-lactams,
aminoglycosides, and fluoroquinolones strictly compromises the choice of an
applicable option for the treatment [5, 6]. β-lactam agents are the main choice to
treat severe infections caused by P. aeruginosa. However, the production of
β-lactamases, such as cephalosporinases and carbapenemases, has been frequently
described among clinical isolates of P. aeruginosa [7]. In P. aeruginosa, the
reduced susceptibility to carbapenems is due to the acquired carbapenemases in
combination with intrinsic mechanisms such as downexpression or absence of
OprD porin, efflux pumps system overexpression, chromosomal AmpC β-lactamase
production, and target modifications. However, carbapenemases have an extended
substrate spectrum to penicillins and cephalosporins, besides carbapenems.
Therefore, carbapenemase-producing bacterial strains commonly exhibit resistance
to virtually all β-lactams [8]. The carbapenem molecules are more stable against
hydrolysis by the most serine-β-lactamases; these drugs have a particular value in
the treatment of infections caused by cephalosporinase-producing bacteria, which
remain susceptible to carbapenems [9]. Car-R/Ceph-S P. aeruginosa have been
reported by few studies [9, 10]. Since these P. aeruginosa do not produce high
levels of AmpC, theoretically ceftazidime or cefepime could be prescribed for
treatment of such infections [9, 10]. We aimed to investigate the mechanisms of
carbapenem resistance in clinical isolates of Car-R/Ceph-S P. aeruginosa from Iran.
Methods
Patients and isolates
A total of 243 P. aeruginosa isolates were collected from infected patients in
Azerbaijan, Iran, during 2016–2018. The isolates were identified by biochemical
and standard methods of microbiology. The disk diffusion method was used for
the initial detection of Car-R/Ceph-S (ceftazidime or cefepime) isolates.
The demographic and clinical information, such as gender, age, duration of
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hospitalization, intensive care unit (ICU) stay, and the treatment outcome, was
collected. Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were
used as quality control strains for standard microbiology testing.
This study was approved by the Ethics Committee of Tabriz University of
Medical Sciences (IR.TBZMED.REC. 1396.306).
Antibiotic susceptibility patterns
The disk diffusion method. The disk diffusion method was performed on Mueller–
Hinton agar according to Clinical and Laboratory Standards Institute (CLSI)
guidelines [11]. Antibiotic disks in this study included ceftazidime, colistin,
levofloxacin, polymyxin B, aztreonam, ciprofloxacin, amikacin, cefepime, and
piperacillin/tazobactam. In this study, MDR was considered as acquired
non-susceptibility to at least one agent in three or more antimicrobial classes
[12]. P. aeruginosa ATCC 27853 was used as quality control strain for suscepti-
bility testing according to CLSI guidelines.
Minimum inhibitory concentration (MIC)
The agar dilution method was performed on Mueller–Hinton agar as
recommended by CLSI guidelines for determination of MIC. The included
antibiotics were ceftazidime, imipenem, cefepime, and meropenem. The results
were interpreted according to the breakpoints of CLSI [11].
Detection of AmpC overproduction
AmpC overproduction was detected by agar plate supplemented with
cloxacillin (250 μg/ml), because cloxacillin inhibits AmpC β-lactamase effects.
At least a twofold decreased concentration of ceftazidime MIC in the presence of
cloxacillin compared to MIC of ceftazidime without cloxacillin was considered as
an AmpC overproduction [7].
Phenotypic detection of efflux pumps
The inhibitory effect of phenylalanine-arginine beta-naphthylamide (PaβN;
as an efflux pump inhibitor) at a concentration of 40 μg/ml on the MIC of
imipenem and meropenem was detected according to previous studies. At least
twofold decreased MIC in the presence of PAβN compared to MIC value without
inhibitor was considered as an overexpression of efflux pumps [13].
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Polymerase chain reaction (PCR)
Total DNA of P. aeruginosa isolates was extracted by CTAB Proteinase K
method [14]. Eleven pairs of primers were used to amplify fragments with sizes
from 232 to 798 bp those as previously described by Poirel et al. [15]. Three
multiplex reactions were defined including set 1 for detection of blaIMP, blaVIM,
and blaSPM; set 2 for detection of blaNDM, blaKPC, blaOXA-48, and blaBIC; and set 3
for detection of blaAIM, blaGIM, blaSIM, and blaDIM. One microliter of total DNA
was subjected to the multiplex PCR in a 25-μl reaction mixture. Reactions were
carried out at 94 °C for 10 min followed by 36 cycles of amplification involving of
30 s at 94 °C, 40 s at 54 °C, and 50 s at 72 °C, with 5 min at 72 °C for the final
extension. The PCR products were detected by electrophoresis in a 2% agarose gel
containing 0.05 mg/L ethidium bromide [15].
Real-time PCR
RNA extraction kit (SinaClon Co., Tehran, Iran) was used for total RNA
extraction from bacterial isolates according to the manufacturer’s instruction. The
extracted RNA was treated with RNase-free DNase I (SinaClon) to remove the
residual DNA. The quantity and quality of the extracted RNA were measured by
NanoDrop spectrophotometer (ND-1000, Wilmington, USA) and the absence of
genomic DNA residuals was detected by PCR using primers of efflux genes. Five
micrograms of DNA-free RNA were used for the synthesis of cDNA by reverse
transcription using M-mulv reverse transcriptase and random hexamer as a primer
(SinaClon), according to the manufacturer’s instructions. Reverse transcriptase
was inactivated by incubation at 70 °C for 10 min. The cDNAs were stored
at −20 °C until use [7]. The expression levels of oprD, mexAB, and mexXY were
measured by one-step real-time quantitative reverse transcription PCR (RT-PCR)
and specific primers as recommended previously. The PCR was carried out in
Rotor-Gene Real-time PCR device (Model RG 3000; Corbett Research, Sydney,
Australia) in duplicate runs by SYBR premix EX TaqII, Tli RNaseH plus (Takara
Bio Inc., Otsu, Shiga, Japan). The transcription level of the constitutively
expressed rpsL housekeeping gene was considered as standardized expression
levels. Gene expression was considered as ratios of the target gene and house-
keeping gene (rpsL) according to a relative quantification determination as
described previously. Reduced oprD expression was considered relevant when
its level was more than twofold lower compared to that of P. aeruginosa PAO1
reference strain [7]. The results represent comparative expression levels for target
genes in isolates compared to the PAO1 wild-type strain. Hyperproduction of
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mRNA for mexB was considered as the cDNA level more than threefold and for
mRNA of mexY tenfold higher than this level in the P. aeruginosa [16].
Statistical analysis
The data were analyzed using the Statistical Package for the Social Sciences
(SPSS, Inc., Chicago, IL) software, version 20. Comparison of the data among
various groups was performed by χ2 and Fisher’s exact tests. The values of
p≤ 0.05 were considered to be statistically significant.
Results
Patients and isolates
According to the disk diffusion results, 116 P. aeruginosa isolates (47.7%)
were carbapenem-resistant. Among the carbapenem-resistant, 23 non-duplicated
isolates (19.8%) were cephalosporin-susceptible that were collected from wound
(43.5%), blood (17.4%), urine (21.7%), respiratory specimen (13%), and middle-
ear discharge (4.3%). The mean age of patients was 38± 24 years and the most
frequent age range of patients was 31–50 years. These patients [13 males (56.6%)
and 10 females (43.5%)] were hospitalized in burn (34.8%), ICU (43.5%) and
internal (8.7%), transplantation (4.3%), surgery (4.3%), and urology (4.3%)
wards. The mean duration of hospitalization was 36± 22 days. The most patients
(25.8%) had 11–20 days of hospitalization, whereas one patient (4.2%) was
hospitalized more than 100 days. Thirteen (56.5%) patients were observed during
the stay in ICU. The death occurred in 7 (30.1%) patients, whereas 5 (21.7%) of
them have stayed in ICU. Cephalosporin consumption was observed in 13 patients
(56.5%). There was no statistically significant association between cephalosporin
consumption and patient outcome or ICU stay. Table I summarizes the clinical
features of patients with Car-R/Ceph-S P. aeruginosa infections.
Antibiotics resistance patterns
All isolates were colistin- and polymyxin B-susceptible; however, different
frequency of resistance was found against other antimicrobial agents including
levofloxacin (87%), ciprofloxacin (87%), aztreonam (87%), cefepime (69.6%),
piperacillin–tazobactam (69.6%), amikacin (65.2%), and ceftazidime (7.4%).
According to the results of disk diffusion method, 20 isolates (87%) were MDR.
MIC50 and MIC90 of imipenem, meropenem, ceftazidime, and cefepime were 16
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and 32, 32 and 64, 4 and 8, 32 and 64, respectively. According to MIC results, all
isolates were ceftazidime-susceptible (MIC≤ 8) and 9 isolates (38.7%) were
cefepime-susceptible (MIC≤ 8). All isolates were meropenem-resistant
(MIC≥ 8) and 21 isolates (90.3%) were imipenem-resistant (MIC≥ 8).
Mechanisms of resistance to carbapenems
Out of 23 Car-R/Ceph-S, none of the isolates were positive for carbape-
nemase genes. Overexpression of AmpC was detected in one (4.3%) isolate that
was ceftazidime-susceptible but cefepime-resistant. In this isolate, a decrease of
ceftazidime MIC was observed in the presence of cloxacillin. One isolate was
negative for all detected mechanisms of carbapenem resistance. Phenotypic assay
for overexpressed efflux pumps was positive in 14 (60.9%) isolates. Among them,
11 isolates (47.3%) showed at least two times decrease in both meropenem and
imipenemMICs in the presence of PAβN, whereas this characteristic was found in










1 19 Burn Wound − + 35 Cure
2 54 Burn Wound + − 20 Cure
3 59 Internal Urine + − 16 Cure
4 47 Burn Wound − − 10 Death
5 61 ICU Urine + + 95 Death
6 53 ICU Respiratory + + 51 Cure
7 60 Urology Urine − − 8 Cure
8 1 ICU Blood + + 59 Death
9 10 Burn Blood − − 21 Cure
10 8 ICU Blood + + 26 Cure
11 24 ICU Blood + − 23 Cure
12 42 ICU Wound + − 36 Cure
13 49 Burn Wound − + 33 Death
14 18 Internal Middle ear + + 13 Cure
15 5 ICU Wound + − 4 Death
16 82 ICU Respiratory + − 56 Cure
17 37 Surgery Urine − + 24 Cure
18 37 ICU Urine + + 143 Death
19 68 Burn Wound − − 54 Cure
20 26 Burn Wound − − 37 Cure
21 83 ICU Respiratory + − 39 Cure
22 35 Surgery Wound − + 15 Cure
23 5 Burn Wound − − 15 Death
Note: ICU: intensive care unit.
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one isolate (4.3%) only by imipenem and in two isolates (8.6%) only by
meropenem in the presence of PAβN. Overexpression of MexAB-OprM and
MexXY-OprM efflux pumps was detected in 12 (52.1%) and 16 (68.8%) of
isolates by the real-time PCR, respectively. Overexpression of both MexAB-
OprM and MexXY-OprM was detected in 11 isolates (47.3%). A total of 16
(68.8%) isolates showed decreased expression of OprD compared to the house-
keeping gene (rpsL). Table II shows the various mechanisms of carbapenem
resistance among our isolates. Our data show that 11 isolates (47.3%) of Car-R/
Ceph-S P. aeruginosa have multifactorial carbapenem resistance mechanisms
including both overexpression of efflux pumps and decreased OprD expression.
Monofactorial mechanisms of carbapenem resistance were detected among 11
isolates (41.7%), which were associated with overexpression of efflux pumps
(6 isolates: 25.8%) and decreased expression of OprD (5 isolates: 21.5%).
Discussion
Carbapenems are the last choice for treatment of many infections caused by
drug-resistant bacterial pathogens. Unfortunately, carbapenem-resistant P. aerugi-
nosa are on the rise. Resistance to carbapenem in P. aeruginosa may be due to a
combination of β-lactamases (especially AmpC) production, porin mutations, efflux
pump systems overexpression, and/or penicillin-binding protein modifications [17].
Multifactorial mechanisms confer increased resistance to carbapenems, but some
β-lactam agents and aminoglycosides may retain in vitro anti-bacterial effects
[7, 17]. This study demonstrated clinical isolates of P. aeruginosa exhibiting
decreased susceptibility to carbapenems but remain cephalosporin-susceptible from
Iranian clinical settings. These phenotypes have been reported from countries such
as China and Brazil [9, 10, 18]. Similar to other studies, high frequency of resistance
was observed in different group of antibiotics including aminoglycosides, quino-
lones, and penicillins [19]. The treatment of infections caused by P. aeruginosa is
commonly problematic due to the high levels of resistance to antibiotics and the
emergence of resistance during therapy [20]. Similar to other studies, all P.
aeruginosa isolates were polymyxin-susceptible [21, 22]. Colistin, also referred
as polymyxin E, is an old, cationic polypeptide antimicrobial agent with significant
in vitro activity against P. aeruginosa, for which it is currently the only available
active antibiotic against MDR isolates. Growing usage of colistin for antibiotic
therapy of infections caused by MDR bacteria may lead to the development of
colistin-resistant strains in some regions. The worldwide frequency of colistin-
resistant P. aeruginosa is low and may be different between countries and over
time [1]. The high frequency of resistance may limit the option for antibiotic therapy
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of infections caused by P. aeruginosa. Therefore, a pattern shift is essential for the
control strategy of P. aeruginosa infections in our setting. In this study, all Car-R/
Ceph-S P. aeruginosa were meropenem-resistant, whereas one isolate was imipe-
nem-susceptible. P. aeruginosamay be non-susceptible to carbapenems by different
mechanisms. The mechanism of meropenem resistance has been complex and
multifactorial [7, 17]. The frequency of MBL production was reported among
carbapenem-resistant P. aeruginosa from 7% to 100% [23, 24]. The MBLs
identified in P. aeruginosa were often the imipenemase and Verona integron-borne
metallo-β-lactamase, and rarely the Sao Paulo metallo-β-lactamase, and German
imipenemase types [24]. In this study, MBL genes were not observed among
carbapenem-resistant but cephalosporin-susceptible (Car-R/Ceph-S) isolates. MBL
enzymes hydrolyze all β-lactams except aztreonam [25]. Similar to other studies, our
data showed that the 23 Car-R/Ceph-S clinical isolates were all non-carbapenemase
producers. The lack of carbapenemase may be the reason of sensitivity to cephalo-
sporin in this phenotype. In this study, all Car-R/Ceph-S isolates were meropenem-
resistant and multifactorial mechanisms were observed in the frequency similar to
carbapenem-resistant caused by one mechanism. In this study, the most common
mechanism of decreased susceptibility to carbapenems was overexpression of efflux
pumps in 17 (73.91) followed by decreased expression of OprD porin detected in
16 (68.8%) isolates. OprD inactivation alone is the source of intermediate suscepti-
bility or resistance to imipenem. Some researchers reported a decrease of OprD as
the most common mechanism of resistance to carbapenems [17, 26]. A study from
Thailand reported the decreased expression of OprD and increased expression of
MexAB-OprM in 93.65% and 92.06% of carbapenem-resistant P. aeruginosa,
respectively [26]. Another study from China reported that mutational-inactivated
oprD genes might be the chief mechanism of resistance to carbapenem; however,
the expression of efflux pumps was not detected in their study [27]. Campana et al.
[9] from Brazil reported a significantly reduced expression or lack of OprD porin
among all (100%) Car-R/Ceph-S P. aeruginosa. Zeng et al. [10] from China
reported reduced expression or lack of OprD porin in 12 of 29 isolates of Car-R/
Ceph-S P. aeruginosa. The development of carbapenem-resistant P. aeruginosa due
to the loss of porin has been reported in clinical settings and also after in vitro
carbapenem exposure. The capability of OprD-mutant choice by carbapenem
exposure may play a significant role in OprD-mutant emergence and it should be
considered regarding empirical clinical usage of carbapenems [9]. Some studies
have reported the expression of efflux pumps as the most common mechanism of
resistance to carbapenems especially meropenem among carbapenem-resistant P.
aeruginosa [7, 28]. In this study, overexpression of MexAB-OprM and
MexXY-OprM efflux pumps was observed in 11 (47.3%) and 16 (68.8%) of
isolates by real-time PCR, respectively. Overexpression of both MexAB-OprM and
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MexXY-OprM was detected in 11 isolates (47.3%). Zeng et al. [10] from China
reported overexpression of the MexAB-OprM, MexCD-OprJ, and MexXY-OprM
efflux systems in 66.67%, 33.33%, and 91.67% of Car-R/Ceph-S isolates, respec-
tively. Overexpression of these efflux systems mediates resistance to meropenem.
We also observed that resistance to cefepime is higher than ceftazidime [all isolates
were ceftazidime-susceptible but 9 isolates (38.7%) were cefepime susceptible].
Other studies have reported the role of efflux pumps in the selectively reduced
susceptibility to cefepime in P. aeruginosa strains [29, 30]. In this study, over-
expression of AmpC, decreased expression of OprD, and overexpression of
MexAB-OprM and MexXY-OprM efflux systems were not detected for one
Car-R/Ceph-S isolate. The resistance to carbapenem in this isolate may be due to
the overexpression of other efflux system such as MexCD-OprJ, which has been
reported in other study [10]. There was no statistically significant association
between cephalosporin consumption and patient outcome or ICU stay. Li et al.
[18] from China reported that several factors such as 30-day readmission, central
venous catheters, and exposure to carbapenems may influence on acquiring Car-R/
Ceph-S P. aeruginosa bacteremia.
In conclusion, we isolated Car-R/Ceph-S P. aeruginosa, which did not
develop resistance by the production of carbapenemase. This phenotype was first
reported from our country. The resistance to imipenem and meropenem in our
clinical isolates was mediated by the decreased expression of OprD and
overexpression of MexAB-OprM and MexXY-OprM efflux systems or the
combination of these mechanisms.
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